Cargando…

Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers

SIMPLE SUMMARY: Ovarian cancer (OvCa) is a prominent cause of cancer death in women due to missed early signs and late diagnoses. Once a woman is diagnosed with OvCa, the standard treatment is surgery to remove the tumor, followed by chemotherapy. Many women go into remission after treatment, but th...

Descripción completa

Detalles Bibliográficos
Autores principales: McFadden, Melayshia, Singh, Santosh Kumar, Oprea-Ilies, Gabriela, Singh, Rajesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582784/
https://www.ncbi.nlm.nih.gov/pubmed/34771642
http://dx.doi.org/10.3390/cancers13215480
_version_ 1784597064654520320
author McFadden, Melayshia
Singh, Santosh Kumar
Oprea-Ilies, Gabriela
Singh, Rajesh
author_facet McFadden, Melayshia
Singh, Santosh Kumar
Oprea-Ilies, Gabriela
Singh, Rajesh
author_sort McFadden, Melayshia
collection PubMed
description SIMPLE SUMMARY: Ovarian cancer (OvCa) is a prominent cause of cancer death in women due to missed early signs and late diagnoses. Once a woman is diagnosed with OvCa, the standard treatment is surgery to remove the tumor, followed by chemotherapy. Many women go into remission after treatment, but there is always a strong possibility that the cancer will return. If the cancer returns in less than 6 months, the patient is considered platinum-resistant and undergoes a new treatment plan. Drug resistance occurs when the cancer cells become resistant to the administered drug during initial chemotherapy, causing the drug to become ineffective. This is a considerable challenge in the cancer field, and many researchers are looking for strategies to overcome this drug resistance. However, nanotechnology, natural products, and RNA interference therapy are strategies that can enhance cancer therapy to overcome drug resistance in cancer cells. ABSTRACT: Ovarian cancer (OvCa) is a destructive malignancy due to difficulties in early detection and late advanced-stage diagnoses, leading to high morbidity and mortality rates for women. Currently, the quality treatment for OvCa includes tumor debulking surgery and intravenous platinum-based chemotherapy. However, numerous patients either succumb to the disease or undergo relapse due to drug resistance, such as to platinum drugs. There are several mechanisms that cause cancer cells’ resistance to chemotherapy, such as inactivation of the drug, alteration of the drug targets, enhancement of DNA repair of drug-induced damage, and multidrug resistance (MDR). Some targeted therapies, such as nanoparticles, and some non-targeted therapies, such as natural products, reverse MDR. Nanoparticle targeting can lead to the reversal of MDR by allowing direct access for agents to specific tumor sites. Natural products have many anti-cancer properties that adversely regulate the factors contributing to MDR. The present review displays the current problems in OvCa treatments that lead to resistance and proposes using nanotechnology and natural products to overcome drug resistance.
format Online
Article
Text
id pubmed-8582784
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85827842021-11-12 Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers McFadden, Melayshia Singh, Santosh Kumar Oprea-Ilies, Gabriela Singh, Rajesh Cancers (Basel) Review SIMPLE SUMMARY: Ovarian cancer (OvCa) is a prominent cause of cancer death in women due to missed early signs and late diagnoses. Once a woman is diagnosed with OvCa, the standard treatment is surgery to remove the tumor, followed by chemotherapy. Many women go into remission after treatment, but there is always a strong possibility that the cancer will return. If the cancer returns in less than 6 months, the patient is considered platinum-resistant and undergoes a new treatment plan. Drug resistance occurs when the cancer cells become resistant to the administered drug during initial chemotherapy, causing the drug to become ineffective. This is a considerable challenge in the cancer field, and many researchers are looking for strategies to overcome this drug resistance. However, nanotechnology, natural products, and RNA interference therapy are strategies that can enhance cancer therapy to overcome drug resistance in cancer cells. ABSTRACT: Ovarian cancer (OvCa) is a destructive malignancy due to difficulties in early detection and late advanced-stage diagnoses, leading to high morbidity and mortality rates for women. Currently, the quality treatment for OvCa includes tumor debulking surgery and intravenous platinum-based chemotherapy. However, numerous patients either succumb to the disease or undergo relapse due to drug resistance, such as to platinum drugs. There are several mechanisms that cause cancer cells’ resistance to chemotherapy, such as inactivation of the drug, alteration of the drug targets, enhancement of DNA repair of drug-induced damage, and multidrug resistance (MDR). Some targeted therapies, such as nanoparticles, and some non-targeted therapies, such as natural products, reverse MDR. Nanoparticle targeting can lead to the reversal of MDR by allowing direct access for agents to specific tumor sites. Natural products have many anti-cancer properties that adversely regulate the factors contributing to MDR. The present review displays the current problems in OvCa treatments that lead to resistance and proposes using nanotechnology and natural products to overcome drug resistance. MDPI 2021-10-31 /pmc/articles/PMC8582784/ /pubmed/34771642 http://dx.doi.org/10.3390/cancers13215480 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
McFadden, Melayshia
Singh, Santosh Kumar
Oprea-Ilies, Gabriela
Singh, Rajesh
Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers
title Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers
title_full Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers
title_fullStr Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers
title_full_unstemmed Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers
title_short Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers
title_sort nano-based drug delivery and targeting to overcome drug resistance of ovarian cancers
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582784/
https://www.ncbi.nlm.nih.gov/pubmed/34771642
http://dx.doi.org/10.3390/cancers13215480
work_keys_str_mv AT mcfaddenmelayshia nanobaseddrugdeliveryandtargetingtoovercomedrugresistanceofovariancancers
AT singhsantoshkumar nanobaseddrugdeliveryandtargetingtoovercomedrugresistanceofovariancancers
AT opreailiesgabriela nanobaseddrugdeliveryandtargetingtoovercomedrugresistanceofovariancancers
AT singhrajesh nanobaseddrugdeliveryandtargetingtoovercomedrugresistanceofovariancancers